Clinical trials: insulin glargine
Type 1 Diabetes Mellitus
Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the 24-hour glycemic profile in continuous glucose monitoring (CGM) between a new formulation of insulin glargine and Lantus at steady state Secondary Objectives: To compare the change of Fasting…
- Trial name
- NCT01676233
- Testing
- insulin glargine (HOE901), insulin glargine- new formulation (HOE901)
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Insulin-requiring Type 2 Diabetes Mellitus
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.
- Trial name
- NCT01500850
- Testing
- nph insulin, human insulin, Insulin Glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- ikfe-CRO GmbH
Type 2 Diabetes Mellitus
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to…
- Trial name
- NCT02551874
- Testing
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin
- Where
- 40 sites in United States, Czechia and 8 more
- Volunteers
- 650 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus.
- Trial name
- NCT05553093
- Testing
- Tirzepatide, Insulin Glargine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes, Inpatient Hyperglycemia
Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
High blood glucose levels in surgical patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- RABBIT 2-SX (NCT00596687)
- Testing
- Insulin glargine, Regular insulin, Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 234 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective: To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
- Trial name
- CHANGING (NCT01203111)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Algeria, Brazil and 8 more
- Volunteers
- 207 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be…
- Trial name
- NCT02623998
- Testing
- insulin glargine, sitagliptin/metformin, lifestyle therapy
- Where
- 6 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Population Health Research Institute
Healthy
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
This is a randomised, double-blind, double-dummy, active-controlled, three-period crossover euglycemic clamp trial in healthy Chinese volunteers. Each subject will be randomly allocated to one of 6 treatment sequences.
- Trial name
- NCT05373186
- Testing
- Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25, Euglycemic clamp with Humalog® and Lantus®
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Adocia
Diabetes Mellitus
Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward
At least 20% of patients hospitalized in the general medical and surgical wards at any given time suffer from diabetes. It has been demonstrated that poor clinical outcome correlates with the degree of hyperglycemia in these…
- Trial name
- NCT00464854
- Testing
- Glargine and insulin aspart or lispro
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week
This study will look at how insulin 287 works, if it is safe and the side effects in people who are Japanese with type 1 diabetes.
- Trial name
- NCT03766854
- Testing
- insulin icodec, Insulin glargine U100
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
This randomized, open-label, parallel arm study will compare the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin-naïve patients with type 2 diabetes mellitus inadequately…
- Trial name
- NCT01051011
- Testing
- insulin glargine, metformin, taspoglutide
- Where
- 56 sites in China, Hong Kong and 5 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in…
- Trial name
- GREAN (NCT00970528)
- Testing
- Acarbose (Glucobay, BAYG5421), Voglibose (Basen)
- Where
- 11 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- Bayer
Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM
In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin once or twice daily plus pre-prandial insulin…
- Conditions
- Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
- Trial name
- NCT04965051
- Testing
- insulin degludec/insulin aspart (IDegAsp), basal insulin plus pre-prandial insulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Type 1 Diabetes
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin…
- Trial name
- NCT07282054
- Testing
- THDB0206, Insulin Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine…
- Trial name
- BEGIN™ (NCT00982228)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 91 sites in United States, France and 4 more
- Volunteers
- 629 people
- Sponsor
- Novo Nordisk A/S